{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:33:21Z","timestamp":1780580001846,"version":"3.54.1"},"reference-count":14,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,12,10]]},"abstract":"<jats:p>Cannabinoid hyperemesis syndrome (CHS) is a rare clinical syndrome characterised by nausea, cyclic vomiting and severe abdominal pain in association with chronic cannabis use. It is often under-recognised or misdiagnosed, resulting in the unnecessary workup and frequent hospitalisations. Long-term treatment of CHS is abstinence from cannabis, but acute symptomatic management has been a struggle for many clinicians. The present report highlights the use of haloperidol as an agent that successfully and safely treats the unrelenting symptoms of CHS.<\/jats:p>","DOI":"10.1136\/bcr-2016-218239","type":"journal-article","created":{"date-parts":[[2017,1,4]],"date-time":"2017-01-04T16:15:29Z","timestamp":1483546529000},"page":"bcr2016218239","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?"],"prefix":"10.1136","volume":"2017","author":[{"given":"Faisal","family":"Inayat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafeez Ul Hassan","family":"Virk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qulsoom","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,1,4]]},"reference":[{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.1","doi-asserted-by":"crossref","first-page":"pii: bcr2015210246","DOI":"10.1136\/bcr-2015-210246","article-title":"Cannabinoid hyperemesis syndrome: a guide for the practicing clinician","volume":"2015","author":"Bajgoric","year":"2015","journal-title":"BMJ Case Rep"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050141"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.3","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2010.06.100117"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2012.11.034"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.5","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3949\/ccjm.82a.14023","article-title":"Cannabinoid hyperemesis syndrome: marijuana is both antiemetic and proemetic","volume":"82","author":"Lu","year":"2015","journal-title":"Cleve Clin J Med"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.6","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2013.1179"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.10.005"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1213\/01.ANE.0000068580.00245.95","article-title":"Consensus guidelines for managing postoperative nausea and vomiting","volume":"97","author":"Gan","year":"2003","journal-title":"Anesth Analg"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.9","unstructured":"Juurlink DN . Antipsychotics. In: Nelson LS , Lewin NA , Howland MA , Hoffman RS , Goldfrank LR , Flomenbaum NE, eds . Goldfrank's toxicologic emergencies. 9th edn. Ch. 69. New York: McGraw Hill, 2011:1003\u201315."},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.10","doi-asserted-by":"crossref","first-page":"1003.e5","DOI":"10.1016\/j.ajem.2013.02.021","article-title":"Haloperidol for treatment of cannabinoid hyperemesis syndrome","volume":"31","author":"Hickey","year":"2013","journal-title":"Am J Emerg Med"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.11","first-page":"1097","article-title":"Haloperidol, a novel treatment for cannabinoid hyperemesis syndrome","volume":"10","author":"Witsil","year":"2014","journal-title":"Am J Ther"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.12","first-page":"3614053","article-title":"Successful treatment of suspected cannabinoid hyperemesis syndrome using haloperidol in the outpatient setting","volume":"2016","author":"Jones","year":"2016","journal-title":"Case Rep Psychiatry"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00213-012-2661-9","article-title":"Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys","volume":"222","author":"Schulze","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"2025042702135024000_2017.jan04_1.bcr2016218239.14","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.198374"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-218239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T09:14:01Z","timestamp":1745745241000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-218239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,4]]},"references-count":14,"alternative-id":["10.1136\/bcr-2016-218239"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-218239","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,4]]}}}